01 8Arnuity Ellipta
02 1Avamys
03 1Avamys / Veramys
04 8Avamys/Veramyst
05 1Relvar
06 1Relvar /Breo Ellipta
07 8Relvar/Breo Ellipta
08 7Trelegy Ellipta
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 412
2019 Revenue in Millions : 449
Growth (%) : -8
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 1,135
2019 Revenue in Millions : 718
Growth (%) : 58
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 1,558
2019 Revenue in Millions : 1,346
Growth (%) : 16
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 62
2019 Revenue in Millions : 67
Growth (%) : -6
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 1,517
2020 Revenue in Millions : 1,540
Growth (%) : 0
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 403
2020 Revenue in Millions : 407
Growth (%) : 0
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 64
2020 Revenue in Millions : 62
Growth (%) : 4
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 1,647
2020 Revenue in Millions : 1,122
Growth (%) : 49
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 1,412
2021 Revenue in Millions : 1,517
Growth (%) : -7
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 396
2021 Revenue in Millions : 403
Growth (%) : -2
LOOKING FOR A SUPPLIER?